Treatment with febuxostat for 24 weeks has resulted in reduced SUA levels, as well as decreased levels of aspartate aminotransferase and alanine aminotransferase in NAFLD patients with hyperuricemia (116). Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.